Geron Corp. buy stratec
Summary
This prediction ended on 28.09.18 with a price of €1.45. Massive losses of -60.44% were the result for the BUY prediction by stratec. stratec has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 3.765% | 3.765% | 46.060% | 260.810% |
| iShares Core DAX® | 0.786% | -0.427% | 17.458% | 17.620% |
| iShares Nasdaq 100 | 2.297% | 7.331% | 38.189% | 53.439% |
| iShares Nikkei 225® | 3.076% | 3.279% | 13.174% | 10.191% |
| iShares S&P 500 | 0.902% | 3.970% | 29.787% | 46.282% |
Comments by stratec for this prediction
In the thread Geron Corp. diskutieren
stratec stimmt der Buy-Einschätzung von tamam zu
stratec stimmt am 164.2018 der Buy-Einschätzung von tamam mit dem Kursziel 6$ zu.
Überschrift: Geron, buyout by J & J , oder bankrott
While biotech giant Celgene (CELG) seems to be making all the headlines lately with two multi-billion-dollar acquisitions, little biotech Geron (GERN) may very well be the David to Celgene's Goliath. Geron's Imetelstat appears to be about twice as effective as Celgene's Revlimid in providing transfusion independence for Myelodysplastic Syndrome, "MDS," patients. Imetelstat also has shown signs of disease modification and remissions in Myelofibrosis, "MF," whereas Fedratinib, the lead drug
candidate of Celgene's recently announced $2.4B acquisition of Impact Biomedicines, appears to be another "me too" Jak-2 Inhibitor with modestly better safety profile than Incyte's (INCY) Jakafi.